Menu Search
Equities

Ipsen SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IPNN:MEX

Ipsen SA

Actions
  • Price (MXN)2,793.85
  • Today's Change0.00 / 0.00%
  • Shares traded789.00
  • 1 Year change--
  • Beta0.3611
Data delayed at least 20 minutes, as of Nov 13 2025 11:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

  • Revenue in EUR (TTM)3.76bn
  • Net income in EUR447.90m
  • Incorporated1998
  • Employees5.36k
  • Location
    Ipsen SA65 Quai Georges GorseBOULOGNE-BILLANCOURT 92100FranceFRA
  • Phone+33 158335000
  • Fax+33 158335001
  • Websitehttps://www.ipsen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		IPN:PAR since
announced		Transaction
value
ImCheck Therapeutics SASDeal completed22 Oct 202522 Oct 2025Deal completed20.34%405.93m
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.